FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																	
1. Name and Address of Reporting Person* BALEZENTIS CARL W				2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]							5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner							
(Last) (First) (Middle) C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 12/07/2007								X Officer (give title below) Other (specify below) President, Enzo Life Sciences						
NEW YORK, NY 10003				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City	r)	(State)	(Zip)	Table I - Non-Derivative Securities Acqu						quire	tired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year	Exect any	2A. Deemed Execution Date, it any (Month/Day/Year		(Instr. 8)		(A) or Disposed of (D) (Instr. 3, 4 and 5)		of	of Beneficia Reported		nt of Securities ally Owned Following Transaction(s) and 4)			p of Be	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							C	ode	V	Amoun	(A) or t (D)	Pric	e				(I) (Instr. 4)	Ì	,
Restricted Stock 12/07/2007		12/07/2007					A		7,500 (1)	A	\$ 0 (1)	2,	,500 (2)		D			
Reminder:	Report on a	separate line fo	r each class of secur					F c t	erso conta he fo	ons who nined in orm dis	respo this fo plays a	rm a	are n rentl	ot requ ly valid	OMB conf	ormation spond unle trol numbe	ss	C 147	74 (9-02)
_		,								convert				Owneu					
Security	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/\footnote{\text{Month/Day/\footnote{\text{V}}}	Execution Da Year) any	te, if Transaction Code ('ear) (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		Ai Ui Se			Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owner Form Deriva Securi Direct or Ind	of tive ty: (D) rect	Beneficia Ownersh (Instr. 4)		
					Code	V	(A)		Date Exerc		Expiration Date	on Ti	itle i	Amount or Number of Shares					

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
BALEZENTIS CARL W C/O ENZO BIOCHEM, INC. 527 MADISON AVENUE NEW YORK, NY 10003			President, Enzo Life Sciences					

Signatures

/s/ Carl Balezentis	12/11/2007	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On December 7, 2007, the Reporting Person was granted 7,500 shares of Restricted Stock as compensation for service as an officer of the Issuer.
- (2) This number does not include 10,000 shares of Restricted Stock that will not vest within 60 days from the date hereof.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.